The American Society for Apheresis provides clinical guidelines for therapeutic apheresis in adults, but there are no guidelines for children. This study aimed to analyze the effect of therapeutic plasma exchange (TPE) in pediatric patients with various kidney diseases in Korea. Methods: We retrospectively reviewed the data of 16 children (up to 18 years of age) who were admitted to Severance Children's Hospital with refractory kidney disease. All patients received TPE between 1994 and 2016. Clinical and laboratory characteristics such as age, weight, sex, change in blood urea nitrogen (BUN), and creatinine level before and after TPE, and complications after TPE were analyzed. Results: The mean age and weight of the 16 patients at the time of TPE was 11.3± 4.0 years and 34.6±17.5 kg, respectively. The BUN level was 35.4 mg/dL before TPE and significantly decreased to 21.5 mg/dL (P=0.025) at 1 week and 20.5 mg/dL (P= 0.01) at 1 month after TPE. The creatinine level significantly decreased from 1.20 mg/dL before TPE to 0.90 mg/dL (P=0.02) at 1 week after TPE. Four complications (hypovolemia, anemia, hypocalcemia, and thrombocytopenia) were reported, but were not fatal. Conclusion: Our findings suggest that TPE is an effective therapeutic modality in children with refractory kidney disease and can be indicated for the treatment of various kidney diseases.
Introduction
Therapeutic plasma exchange (TPE) is a treatment modality to remove cir culating pathologic substances from the plasma and replace them with a sub stitution fluid (e.g., albumin or plasma) 1, 2) . TPE has been applied in various dis eases such as neurological diseases (e.g., myasthenia gravis, GuillainBarré syndrome), hematological disorders (e.g., thrombotic thrombocytopenic pur pura, hemolytic uremic syndrome), metabolic disorders (e.g., inborn errors of metabolism, homozygous familial hypercholesterolemia), and kidney dis eases (e.g., the renal transplant candidate, antibody mediated renal allograft rejection, recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation, antineutrophil cytoplasmic antibodies and antiglomerular basement membrane antibodyassociated rapidly progres sing glomerulonephritis, and atypical hemolytic uremic syndrome (aHUS)) 3) . The first reported plasmapheresis was performed at Johns Hopkins University in 1914 4) . Decades later, the first plasma exchange in a human was conducted in a patient with Wal denstrom's macroglobulinemia in 1960 5) . The TPE techni que was developed gradually and the clinical application of TPE has expanded remarkably. The American Society for Apheresis (ASFA) guideline provides the clinical indi cations for the evidencebased use of therapeutic apheresis in adult studies 6) . In addition, TPE is a widely recognized therapeutic option in pediatric patients as well as in adults. However, there is no guideline for children, especially those with kidney disease.
In a PubMed search, there were about 30 papers regar ding TPE in pediatric patients with kidney disease 79) . There were particularly few studies about TPE in children with kidney disease in Korea 10) . Therefore, further study of TPE in pediatric patients with kidney diseases is warranted.
TPE is an important treatment modality for children with renal and other immunemediated diseases 3) . For the continued development of TPE as an optimal treatment modality in pediatric patients, accurate data are required based on longterm experience.
The purpose of this study was to review the data of pe diatric patients with kidney diseases treated with TPE at a single institution over the last 23 years in terms of etiologies, characteristics, complications, and clinical outcomes.
Materials and methods

Patients
We retrospectively reviewed the data of children (up to 18 years of age) who underwent TPE between 1994 and 2016 in Severance Children's Hospital. We identified 37 children admitted to Severance Children's Hospital who had undergone TPE during the study period. Among them, there were 19 patients (51.3%) with kidney diseases, 9 patients (24.3%) with neurologic diseases, and 7 patients (18.9%) with hepatic diseases. Three of the patients with kidney diseases were excluded due to missing data; thus, 16 patients (2 male and 14 female) with kidney diseases were included in this study.
Data collection
The patients' medical records were obtained from the nephrology department and data including patients' de mographic and clinical characteristics (age, sex, body weight, indication for TPE, treatment, prognosis), main features of the TPE procedures (frequency of TPE, site of initial vascular access, type of replacement fluid, plasma volume), and complications were analyzed. Blood urea ni trogen (BUN), serum creatinine, C3, C4, proteinuria and serum albumin levels were measured before and after TPE, and the values were compared.
TPE procedure
Effective volume was calculated as effective plasma vo lume (mL)=body weight×70 mL/kg×(1hematocrit). TPE was performed every other day, and a total 11.5 volume of plasma was exchanged, depending on patients' weight and hematocrit. The replacement fluids were albumin 4% and/ or fresh frozen plasma (FFP) according to the indication for TPE. A doublelumen hemodialysis central venous catheter was inserted through the jugular, subclavian, or femoral vein according to the patient's vascular anatomy. TPE was performed using COBE Spectra (Thermo BCT Inc., Lake wood, CO, USA) by centrifugation.
Statistical analysis
Continuous variables are expressed as the mean±standard deviation or medians with ranges. Data were analyzed with a paired ttest. All statistical analyses were performed by using SPSS software (version 22.0, IBM Corporation, Armonk, NY, USA) and a P value less than 0.05 was con sidered statistically significant.
Results
Demographic data
From April 1994 to February 2016 a total of 16 patients with kidney diseases who were younger than 18 years underwent TPE. The clinical characteristics of the patients are shown in Table 1 . There were two male and 14 female patients. The mean age at onset was 11.3±4.0 years and the body weight was 34.6±17.5 kg.
Therapeutic effects of TPE
In this study, three patients underwent more than one TPE session, resulting in a total of 19 TPE sessions. Some patients responded very well to the first TPE session, but subsequently needed another course of TPE for the same or a different indication.
In the present study, the etiologies for TPE were lupus nephritis (9 patients), FSGS (4 patients), DenysDrash syndrome (1 patient), microscopic polyarteritis (1 patient), and aHUS (1 patient). The patients were divided into four groups depending on the reason for TPE: refractory (12 patients), recurrent (2 patients), rejection (1 patient), and others (4 patients) ( Table 1 ). The refractory group comprised patients who had no response to steroid, cyclophospha mide, methylprednisolone, azathioprine, and cyclosporine treatment. The recurrent group comprised patients who presented recurrence after kidney transplantation, and the rejection groups comprised patients who presented acute rejection after kidney transplantation.
The comparison between laboratory values (BUN and serum creatinine) before and after TPE is shown in Table  1 . BUN level at 1 week significantly decreased from 35.4 mg/dL to 21.5 mg/dL (P=0.025) and creatinine level signifi cantly decreased from 1.20 mg/dL to 0.90 mg/dL (P=0.02). BUN level at 1 month after TPE significantly decreased from 35.4 mg/dL to 20.5 mg/dL (P=0.01) (Table 4) .
Also, in order to investigate the TPE effect in patients with lupus nephritis, C3, C4 and proteinuria values before and after TPE are shown in Table 2 . In addition, AntiDNA Ab titer was investigated for TPE effect evaluation in lupus nephritis ( Table 2 ). Among the children with lupus ne phritis, six patients were found to have increased antiDNA Ab titer before TPE. In addition, antiDNA Ab titer de creased in 3 patients (patient 2, 5, 9) after TPE, and there was no difference in 5 patients (patient 1, 3, 4, 6, 8) after TPE ( Table 2) .
And serum albumin and proteinuria values before and after TPE are shown in Table 3 to reveal the TPE effect in FSGS patients. In patients with lupus nephritis, C3 level and C4 level at 1 month after TPE increased from 34 mg/dL to 51.1 mg/dL (P=0.082) and from 6.9 mg/dL to 9.5 mg/dL (P= 0.18), respectively. However, these results were not statistic ally significant compared to those in BUN and creatinine (Table 5 ). In patients with FSGS, albumin at 1 month after TPE increased from 2.6 g/dL to 3.1 g/dL (P= 0.322), but was not statistically significant (Table 6 ). 
Clinical outcomes
Among the 16 patients, 3 patients received kidney trans plantation and 3 patients were treated with hemodialysis due to endstage renal disease (ESRD). A complete response was defined as a patient who was treated after TPE with no more following up. A partial response was defined as pa tients without proteinuria after TPE or other treatments and patients with wellcontrolled proteinuria (proteinuria 1+). Complete response was observed in 1 patient (patient 16), and partial response was observed in 5 patients (patient 3, 5, 6, 11 and 13). Three of nine patients with lupus nephritis and two of four patients with FSGS showed partial response. One patient was eventually expired (patient 7).
TPE procedure and complications
The 16 patients underwent a total of 104 sessions. The average frequency of TPE per each case was 5.5±3.8 ses sions, and the procedures were carried out using a central venous catheter. The type of vascular access was chosen based on the patient's vascular anatomy and the most com mon site was the subclavian vein (8 cases), followed by the internal jugular vein (5 cases). The replacement fluids were 4% albumin (9 cases, 47%) or FFP (5 cases, 26%) according to the patients' general condition. Four compli cations were reported for the 104 TPE sessions (hypovo lemia, anemia, hypocalcemia, and thrombocytopenia) ( Table 7) .
Discussion
Although TPE has been increasingly used as a firstline therapy in the last few decades, there is a lack of research about TPE in pediatric kidney diseases. Therefore, the aim of this study was to analyze the therapeutic effect of TPE in pediatric kidney diseases 11, 12) . In 1980, plasmapheresis was introduced in Korea, and the first procedure was performed in Severance Hospital in a patient with membranous proliferative glomerulo nephritis in 1981. TPE nonselectively removes pathogenic substances or replaces a deficient factor, as in systemic thrombotic microangiopathy 3) . The ASFA Special Issue, 7th edition, published in 2016 classifies disorders into four categories. Category I is accepted as firstline therapy, and category II is accepted as supportive or adjunctive therapy. However, category III is not established, and category IV is ineffective or harmful 6) . There are few published reports about TPE conducted in pediatric patients, thus, the indi cations for TPE in children are based on those in adults. Song et al. showed that the most common indications of TPE in the nationwide survey on Korea were myasthenia gravis (15.3%), followed by thrombotic thrombocytopenic purpura (TTP) (14.5%), and HUS (9.7%) 13) . Volder et al.
showed that TPE indications in pediatric and adolescent patients from the World Apheresis registry data were neu rological diseases (33%) and renal diseases (17%). Paglia longa et al. reported that the indications of TPE in European pediatric nephrology units were FSGS (16.4%) and HUS/ TTP (17.9%) 8, 14) . In addition, Reddy et al. reported that the etiologies for TPE were aHUS (75%), antiglomerular base ment membrane disease (12.5%), lupus nephritis (6.25%), and microscopic polyangiitis (6.25%) ( Table 8) 15) . In our singlecenter study, the indications of TPE in pediatric patients with kidney diseases were lupus nephritis (52.6%), FSGS (31.6%), and HUS/TTP (15.8%).
TPE in lupus nephritis is classified as Category IV accor ding to the ASFA. Lewis et al. showed that TPE in combi nation with prednisolone and cyclophosphamide is not as effective for the treatment of lupus nephritis as compared with prednisolone and cyclophosphamide alone 6) . On the contrary, Li et al. reported that lupus nephritis patients with thrombotic microangiopathy who underwent TPE had a significantly higher rate of remission than those who did not undergo TPE 16, 17) . In this study, TPE in a lupus nephritis patient with thrombotic TTP (patient 5) had a clinical effect. Currently, the patient has no proteinuria and is re gularly followed up at the outpatient clinic. Among the remaining lupus nephritis patients who underwent TPE, no children have progressed to ESRD, 3 patients (patient 3, patient 5, and patient 6) are undergoing outpatient obser vation and 3 patients (patient 1, patient 2, and patient 8) failed to attend follow up visits in our clinic. In addition, 1 patient (patient 4) moved to another hospital after improve ment, and 1 patient (patient 7) died due to exacerbation of pneumonia. While TPE for lupus nephritis is classified as Category IV according to the ASFA, the results of the pre sent study show that TPE has some effect on lupus nephritis.
In a review article by Ponticelli et al., 70% of recurrent FSGS children who underwent TPE presented complete or partial remission, and according to Straatmann et al., early TPE was 100% effective in patients with recurrent FSGS 18, 19) . In this study, the patient (patient 11) with recurrent FSGS who underwent TPE 6 days after kidney transplantation presented complete remission. However, the patient (patient 10) with recurrent FSGS who underwent TPE 4 months after kidney transplantation progressed to ESRD and was on hemodialysis. Therefore, early TPE in patients with re current FSGS may be important to improve the prognosis.
The ASFA guideline classifies TTP for ABO incompatible 8, 20) . None of the complications led to death, and all were resolved. Although TPE is a safe and effective therapeutic tool, Pamela et al. reported that among patients hospitalized with ASFA Ca tegory I or II disease, only 13.4% and 9.3% underwent TPE, respectively 21) . In this study, when TPE was performed in patients with diseases corresponding to ASFA Category I and II, TPE was clinically effective in 5 (patient 9, 11, 13, 14, and 16) of 6 patients, and only 1 patient (patient 15) was on hemodialysis due to progressed ESRD. Therefore, it is thought that TPE will be helpful as therapeutic modality in children with kidney disease.
When TPE is performed, albumin and FFP are most commonly used as replacement fluid. Regarding the ad vantages and disadvantages of each fluid, albumin is rela tively expensive but has a lower risk of transfusiontrans mitted infection. FFP maintains the activity of all blood coagulation factors but has a high risk of viral transmission and more frequent adverse reactions such as allergic reac tions 22, 23) . Albumin is used more than plasma due to the lower risk of allergic reactions and transmission of viral infections by plasma 24) . In this study, albumin (47%) was used more frequently than FFP (26%). Depending on the underlying disease and the laboratory findings, the selec tion of appropriate replacement fluid is important.
Carter et al. reported that catheterrelated complications such as catheterrelated thrombosis and infection were common when TPE was used in pediatric patients 3) . Ca theterrelated complications should be considered when performing TPE in children, but these were not reported in this study. Additional considerations for the improve ment of TPE outcomes in children include safe sedation in noncooperative patients and vascular access methods.
Overall, the present study has some limitations including its retrospective design and the inclusion of a small number of patients. As TPE was used in combination with immu nosuppressive therapy, the therapeutic effect of TPE alone was not evaluated in this study. In addition, insurance related factors may have affected the results of our study. For example, the category proposed by ASFA for certain diseases such as FSGS was changed from Category III in 2007 to Category I in 2010. In Korea, we decided to apply insurance based on the ASFA guideline, so patient 12 in this study who underwent TPE in 2008 did not receive insurance benefits 25, 26) . If insurance was more applicable to TPE, it will be helpful in treating children with many kidney diseases.
In conclusion, TPE may be a safe and effective treatment in pediatric kidney disease patients and can be indicated for the treatment various kidney diseases. Further studies are necessary to investigate the overall results in other hospitals and institutions in Korea.
